close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Anti-Cholinergic Drugs Linked to Cognitive Impairment in Elderly

Anti-Cholinergic Drugs Linked to Cognitive Impairment in Elderly

The use of anti-cholinergic drugs by older patients has been linked with mild cognitive impairment, according to a new study in France.

Results of the study were published online on BMJ.com and reported by MedPage Today on February 1, 2006.

An anti-cholinergic drug is one that opposes or blocks the action of the neurotransmitter acetylcholine. Drugs with anti-cholinergic effects include some bronchodilators, antihistamines, analgesics, anti-hypertensives, antidepressants, antiparkinsonian agents and corticosteroids.

Elderly patients taking any of these drugs may consequently experience "significant deficits in cognitive functioning," according to Marie Ancelin, PhD, a senior research fellow at the French national health research unit.

Patients who experience these deficits as a result of taking anti-cholinergic drugs are "highly likely to be classified as mildly cognitively impaired," Dr Ancelin and colleagues reported. A further complicating factor is that these people, once diagnosed with mild cognitive impairment, may receive prescriptions for acetylcholinesterase inhibitors, which inhibit breakdown of acetylcholine.

The researchers therefore advised that physicians prescribing for this patient population should assess the cholinergic effects of their current drug regimen before prescribing an acetylcholinesterase inhibitor.

Clinical Study

Dr Ancelin and colleagues conducted a longitudinal cohort study in the Montpellier region, east of Marseilles. The trial involved 372 participants over age 60 years who showed no signs of dementia when recruited.

The researchers then analyzed each participant's cholinergic burden of drugs, administered annual tests and conducted a neurological assessment at eight years on the participants remaining in the study.

The results showed that 297 participants had taken no anti-cholinergic drugs either at baseline or in the following year, while 30 participants had continually taken at least one anti-cholinergic drug. Other participants had either stopped or started taking these drugs during the year and were excluded.

The results also showed that:

  • 80% of the continual anti-cholinergic drug users had mild cognitive impairment, compared with 35% of non-users.
  • Anti-cholinergic drug use was a strong predictor of mild cognitive impairment (after adjusting for age, sex, education, treated hypertension and untreated depression).
  • Participants who continually used anti-cholinergic drugs performed worse on reaction time, attention, delayed non-verbal memory, narrative recall, visuospatial construction and language tasks, but not on tasks of reasoning, immediate and delayed recall of word lists and implicit memory.
  • At the eight-year follow-up point, all participants had a similar risk of developing dementia: 16% for continual anti-cholinergic drug users versus 14% for non-users.

Dr Ancelin and colleagues noted that, in research into mild cognitive impairment, pro-cholinergic drugs such as Aricept (donepezil) or Reminyl (galantamine) are often used to slow the progress to dementia.

"People with mild cognitive impairment due to anti-cholinergic drugs could be in the absurd situation of receiving pro-cholinergic drugs to counteract the effects of anti-cholinergic agents," the researchers reportedly said.

Sources:
Drug Side Effects Can Befuddle Elderly Brains, MedPage Today, February 1, 2006.
Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. Ancelin ML et al, British Medical Journal, 2006.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...